BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33780283)

  • 21. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
    Beltran H; Antonarakis ES; Morris MJ; Attard G
    Am Soc Clin Oncol Educ Book; 2016; 35():131-41. PubMed ID: 27249694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
    Beltran H; Prandi D; Mosquera JM; Benelli M; Puca L; Cyrta J; Marotz C; Giannopoulou E; Chakravarthi BV; Varambally S; Tomlins SA; Nanus DM; Tagawa ST; Van Allen EM; Elemento O; Sboner A; Garraway LA; Rubin MA; Demichelis F
    Nat Med; 2016 Mar; 22(3):298-305. PubMed ID: 26855148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
    Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
    Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.
    Nava Rodrigues D; Casiraghi N; Romanel A; Crespo M; Miranda S; Rescigno P; Figueiredo I; Riisnaes R; Carreira S; Sumanasuriya S; Gasperini P; Sharp A; Mateo J; Makay A; McNair C; Schiewer M; Knudsen K; Boysen G; Demichelis F; de Bono JS
    Clin Cancer Res; 2019 Jan; 25(2):687-697. PubMed ID: 30257982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.
    Kwan EM; Dai C; Fettke H; Hauser C; Docanto MM; Bukczynska P; Ng N; Foroughi S; Graham LK; Mahon K; Tan W; Wang X; Zhao Z; Zheng T; Zhou K; Yu J; Du P; Horvath LG; Jia S; Kohli M; Azad AA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
    Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
    BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
    Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
    Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
    Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
    Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
    Jayaram A; Wingate A; Wetterskog D; Wheeler G; Sternberg CN; Jones R; Berruti A; Lefresne F; Lahaye M; Thomas S; Gormley M; Meacham F; Garg K; Lim LP; Merseburger AS; Tombal B; Ricci D; Attard G
    Ann Oncol; 2021 Jun; 32(6):726-735. PubMed ID: 33794293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
    Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
    Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
    Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
    Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
    Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
    Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
    Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
    Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.